QSAM Biosciences (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions, today announced the addition of the Ellis Fischel Cancer Center at the University of Missouri School of Medicine as an upcoming clinical trial site. The trial will soon begin enrolling participants into the phase 1 study evaluating CycloSam for participants with multiple types of cancer that either originated in or has metastasized to the bone. “We are pleased and excited to bring on the team at the Ellis Fischel Cancer Center with their experience and resources to continue to advance our clinical development program for CycloSam,” said QSAM CEO Douglas R. Baum. “We are looking forward to their active participation in completing this clinical trial in 2023 and working with us on the next phase of development later this year.”
To view the full press release, visit https://ibn.fm/c7QkK
About QSAM Biosciences Inc.
QSAM Biosciences is developing next-generation nuclear medicines targeting cancer and related diseases. QSAM’s initial technology, CycloSam(R) (Samarium-153 DOTMP), is a clinical-stage bone-targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed the FDA-approved radiopharmaceutical product Quadramet(R) (Samarium-153 EDTMP). The QSAM team has designed CycloSam with the goal of overcoming the clinical limitations of Quadramet(R). QSAM is led by an experienced executive team and board of directors that have completed numerous FDA approvals and multiple successful biotech exits. For more information, visit the company’s website at https://QSAMBio.com.
NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork